Immunotoxins are antibody-toxin fusion proteins directed to kill cancer cells displaying specific target antigens on their surface. Remarkably, immunotoxins directed to CD22 on hairy cell leukemia have produced complete remissions in approximately 60% of patients enrolled in phase I/II trials. For reasons that are not yet clear, 40% of patients responded less well. In addition, patients with other CD22-positive malignancies have not yet achieved complete remissions. In trying to understand 'r...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
If you are the owner of this record, you can report an update to it here: Report update to this record